Literature DB >> 11913951

The effects of the Epstein-Barr virus latent membrane protein 2A on B cell function.

M Merchant1, R Swart, R B Katzman, M Ikeda, A Ikeda, R Longnecker, M L Dykstra, S K Pierce.   

Abstract

Epstein-Barr Virus (EBV) infects B-lymphocytes circulating through the oral epithelium and establishes a lifelong latent infection in a subset of mature-memory B cells. In these latently infected B cells, EBV exhibits limited gene expression with the latent membrane protein 2A (LMP2A) being the most consistently detected transcript. This persistent expression, coupled with many studies ofthe function of LMP2A in vitro and invivo, indicates that LMP2A is functioning to control some aspect of viral latency. Establishment and maintenance of viral latency requires exquisite manipulation of normal B cell signaling and function. LMP2A is capable of blocking normal B cell signal transduction in vitro, suggesting that LMP2A may act to regulate lytic activation from latency in vivo. Furthermore, LMP2A is capable of providing B cells with survival signals in the absence of normal BCR signaling. These data show that LMP2A may help EBV-infected cells to persist in vivo. This review discusses the advances that have been made in our understanding of LMP2A and the effects it has on B cell development, activation, and viral latency.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11913951     DOI: 10.3109/08830180109045591

Source DB:  PubMed          Journal:  Int Rev Immunol        ISSN: 0883-0185            Impact factor:   5.311


  14 in total

Review 1.  Epstein-Barr virus-associated B-cell lymphomas: pathogenesis and clinical outcomes.

Authors:  Abhik Saha; Erle S Robertson
Journal:  Clin Cancer Res       Date:  2011-03-03       Impact factor: 12.531

2.  Post-transplant lymphoproliferative disorders: role of viral infection, genetic lesions and antigen stimulation in the pathogenesis of the disease.

Authors:  Daniela Capello; Gianluca Gaidano
Journal:  Mediterr J Hematol Infect Dis       Date:  2009-12-14       Impact factor: 2.576

3.  Rescue of "crippled" germinal center B cells from apoptosis by Epstein-Barr virus.

Authors:  Christoph Mancao; Markus Altmann; Berit Jungnickel; Wolfgang Hammerschmidt
Journal:  Blood       Date:  2005-08-02       Impact factor: 22.113

4.  LMP2A does not require palmitoylation to localize to buoyant complexes or for function.

Authors:  Rebecca B Katzman; Richard Longnecker
Journal:  J Virol       Date:  2004-10       Impact factor: 5.103

5.  Epstein-Barr virus latent membrane protein 2 effects on epithelial acinus development reveal distinct requirements for the PY and YEEA motifs.

Authors:  Julie A Fotheringham; Nancy Raab-Traub
Journal:  J Virol       Date:  2013-10-09       Impact factor: 5.103

6.  Epstein-Barr Virus (EBV) Tegument Protein BGLF2 Promotes EBV Reactivation through Activation of the p38 Mitogen-Activated Protein Kinase.

Authors:  XueQiao Liu; Jeffrey I Cohen
Journal:  J Virol       Date:  2015-11-11       Impact factor: 5.103

7.  Epstein-Barr virus latent membrane protein-2A-induced DeltaNp63alpha expression is associated with impaired epithelial-cell differentiation.

Authors:  J A Fotheringham; S Mazzucca; N Raab-Traub
Journal:  Oncogene       Date:  2010-05-24       Impact factor: 9.867

8.  Latent Membrane Protein LMP2A Impairs Recognition of EBV-Infected Cells by CD8+ T Cells.

Authors:  Chiara Rancan; Leah Schirrmann; Corinna Hüls; Reinhard Zeidler; Andreas Moosmann
Journal:  PLoS Pathog       Date:  2015-06-11       Impact factor: 6.823

Review 9.  EBV and Apoptosis: The Viral Master Regulator of Cell Fate?

Authors:  Leah Fitzsimmons; Gemma L Kelly
Journal:  Viruses       Date:  2017-11-13       Impact factor: 5.048

10.  The Gammaherpesvirus m2 protein manipulates the Fyn/Vav pathway through a multidocking mechanism of assembly.

Authors:  Marta Pires de Miranda; Marta Alenquer; Sofia Marques; Lénia Rodrigues; Filipa Lopes; Xosé R Bustelo; J Pedro Simas
Journal:  PLoS One       Date:  2008-02-27       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.